BACKGROUND: Patients with germ cell tumours (GCT) receiving cisplatin-based chemotherapy are at high risk of thromboembolic events (TEE). Previously, we identified serum lactate dehydrogenase (LDH) and body surface area (BSA) as independent predictive factors for TEE. The aim of this study was to validate these predictive factors and to assess the impact of thromboembolism prophylaxis in patients at risk of deep venous thrombosis (DVT). METHODS: Between 2001 and 2014, 295 patients received first-line cisplatin-based chemotherapy for GCT. Preventive anticoagulation with low-molecular-weight heparin (LMWH) was progressively implemented in patients with predictive factors. Sixteen patients with evidence of TEE before starting chemotherapy were excluded from the analysis. RESULTS: Among 279 eligible patients, a TEE occurred in 38 (14%) consisting of DVT (n = 26), arterial thrombosis (n = 2), and superficial thrombophlebitis (n = 10). DVT occurred in 26 (12.7%) of 204 patients with risk factors versus two (2.6%) of 75 patients with no risk factors (p = 0.01). After a prevention protocol was progressively implemented from 2005, primary thromboprophylaxis was administered to 104 patients (68%) with risk factors. Among patients at risk (n = 151), the incidence of DVT decreased by roughly half when they received a LMWH: 9/97 (9.2%) and 9/54 (16.6%), respectively (p = 0.23). CONCLUSION: Patients with GCT who receive cisplatin-based chemotherapy are at risk of developing a TEE which can be predicted by elevated serum LDH. To our knowledge this is the first study exploring LMWH as thromboprophylaxis in GCT patients. A prospective trial testing prophylactic anticoagulation is warranted. Copyright Â
BACKGROUND:Patients with germ cell tumours (GCT) receiving cisplatin-based chemotherapy are at high risk of thromboembolic events (TEE). Previously, we identified serum lactate dehydrogenase (LDH) and body surface area (BSA) as independent predictive factors for TEE. The aim of this study was to validate these predictive factors and to assess the impact of thromboembolism prophylaxis in patients at risk of deep venous thrombosis (DVT). METHODS: Between 2001 and 2014, 295 patients received first-line cisplatin-based chemotherapy for GCT. Preventive anticoagulation with low-molecular-weight heparin (LMWH) was progressively implemented in patients with predictive factors. Sixteen patients with evidence of TEE before starting chemotherapy were excluded from the analysis. RESULTS: Among 279 eligible patients, a TEE occurred in 38 (14%) consisting of DVT (n = 26), arterial thrombosis (n = 2), and superficial thrombophlebitis (n = 10). DVT occurred in 26 (12.7%) of 204 patients with risk factors versus two (2.6%) of 75 patients with no risk factors (p = 0.01). After a prevention protocol was progressively implemented from 2005, primary thromboprophylaxis was administered to 104 patients (68%) with risk factors. Among patients at risk (n = 151), the incidence of DVT decreased by roughly half when they received a LMWH: 9/97 (9.2%) and 9/54 (16.6%), respectively (p = 0.23). CONCLUSION:Patients with GCT who receive cisplatin-based chemotherapy are at risk of developing a TEE which can be predicted by elevated serum LDH. To our knowledge this is the first study exploring LMWH as thromboprophylaxis in GCT patients. A prospective trial testing prophylactic anticoagulation is warranted. Copyright Â
Authors: Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu Journal: Curr Opin Oncol Date: 2017-05 Impact factor: 3.645
Authors: Yanfeng Wang; Chanjuan Cui; Xin Liu; Lei Deng; Ke Yang; Bin Li; Jie Xue; Junying Xie; Wei Cui Journal: Thorac Cancer Date: 2022-05-13 Impact factor: 3.223
Authors: Tim Nestler; Johannes Huber; Adrienne M Laury; Hendrik Isbarn; Axel Heidenreich; Hans U Schmelz; Christian G Ruf Journal: World J Urol Date: 2018-02-07 Impact factor: 4.226
Authors: Harmke J Groot; Flora E van Leeuwen; Sjoukje Lubberts; Simon Horenblas; Ronald de Wit; J Alfred Witjes; Gerard Groenewegen; Philip M Poortmans; Maarten C C M Hulshof; Otto W M Meijer; Igle J de Jong; Hetty A van den Berg; Tineke J Smilde; Ben G L Vanneste; Maureen J B Aarts; Katarzyna Jóźwiak; Alexandra W van den Belt-Dusebout; Jourik A Gietema; Michael Schaapveld Journal: Cancer Date: 2019-11-15 Impact factor: 6.860
Authors: Ben Tran; Jose M Ruiz-Morales; Enrique Gonzalez-Billalabeitia; Anna Patrikidou; Eitan Amir; Christoph Seidel; Carsten Bokemeyer; Christian Fankhauser; Thomas Hermanns; Alexey Rumyantsev; Alexey Tryakin; Margarida Brito; Aude Fléchon; Edmond Michael Kwan; Tina Cheng; Daniel Castellano; Xavier Garcia Del Muro; Anis A Hamid; Margaret Ottaviano; Giovannella Palmieri; Robert Kitson; Alison Reid; Daniel Y C Heng; Philippe L Bedard Journal: Cancer Med Date: 2019-11-12 Impact factor: 4.452